121 related articles for article (PubMed ID: 3802026)
1. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs.
Welander CE
Cancer; 1987 Feb; 59(3 Suppl):617-9. PubMed ID: 3802026
[TBL] [Abstract][Full Text] [Related]
2. Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs.
Welander CE
Invest New Drugs; 1987; 5 Suppl():S47-59. PubMed ID: 3298133
[TBL] [Abstract][Full Text] [Related]
3. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay.
Welander CE; Morgan TM; Homesley HD; Trotta PP; Spiegel RJ
Int J Cancer; 1985 Jun; 35(6):721-9. PubMed ID: 4008100
[TBL] [Abstract][Full Text] [Related]
4. Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin.
Von Hoff DD; Sarosy G; Brown TD; Kuhn JG; Kisner DL
Semin Oncol; 1986 Sep; 13(3 Suppl 2):72-7. PubMed ID: 3764442
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Markman M; Berek JS; Blessing JA; McGuire WP; Bell J; Homesley HD
Gynecol Oncol; 1992 Apr; 45(1):3-8. PubMed ID: 1601332
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal alpha interferon for ovarian cancer: a case report.
Carney-Gersten P; Moore MD; Giuffre M
Oncol Nurs Forum; 1990; 17(3):403-7. PubMed ID: 2342974
[TBL] [Abstract][Full Text] [Related]
7. Interferons in the treatment of multiple myeloma.
Cooper MR; Welander CE
Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
12. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
Niloff JM; Knapp RC; Jones G; Schaetzl EM; Bast RC
Cancer Treat Rep; 1985; 69(7-8):895-6. PubMed ID: 4016797
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon.
Berek JS
Eur J Cancer; 1992; 28A(4-5):719-21. PubMed ID: 1524888
[No Abstract] [Full Text] [Related]
14. Effects of cloned human leukocyte interferons in the human tumor stem cell assay.
Salmon SE; Durie BG; Young L; Liu RM; Trown PW; Stebbing N
J Clin Oncol; 1983 Mar; 1(3):217-25. PubMed ID: 6686847
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
17. Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.
Beller U; Chachoua A; Speyer JL; Sorich J; Dugan M; Liebes L; Hayes R; Beckman EM
Gynecol Oncol; 1989 Sep; 34(3):407-12. PubMed ID: 2788602
[TBL] [Abstract][Full Text] [Related]
18. Interferons in the treatment of multiple myeloma.
Cooper MR
Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
D'Acquisto R; Markman M; Hakes T; Rubin S; Hoskins W; Lewis JL
J Clin Oncol; 1988 Apr; 6(4):689-95. PubMed ID: 3128649
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer.
Bezwoda WR; Seymour L; Dansey R
Cancer; 1989 Sep; 64(5):1029-33. PubMed ID: 2758381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
